Q2 EPS Estimate for Cartesian Therapeutics Cut by Analyst

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at HC Wainwright decreased their Q2 2026 earnings estimates for Cartesian Therapeutics in a research note issued on Tuesday, May 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.89) per share for the quarter, down from their previous forecast of ($0.85). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($1.11) EPS, FY2026 earnings at ($4.38) EPS, Q1 2027 earnings at ($1.15) EPS, Q2 2027 earnings at ($1.00) EPS, Q3 2027 earnings at ($0.84) EPS and Q4 2027 earnings at ($0.86) EPS.

Several other analysts have also commented on RNAC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cartesian Therapeutics in a research report on Friday, March 27th. Wedbush reiterated an “outperform” rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research report on Friday, May 1st. Cantor Fitzgerald upgraded shares of Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price target on the stock in a research report on Monday, March 9th. BTIG Research reiterated a “buy” rating on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price target on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.00.

Cartesian Therapeutics Price Performance

RNAC stock opened at $8.42 on Thursday. The company’s 50 day simple moving average is $6.96 and its 200-day simple moving average is $7.21. The firm has a market capitalization of $247.38 million, a PE ratio of -1.43 and a beta of 0.58. Cartesian Therapeutics has a 12 month low of $5.60 and a 12 month high of $15.57.

Cartesian Therapeutics (NASDAQ:RNAC) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.62). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.22 million.

Hedge Funds Weigh In On Cartesian Therapeutics

A number of hedge funds have recently made changes to their positions in RNAC. Rhumbline Advisers boosted its holdings in shares of Cartesian Therapeutics by 27.5% in the 1st quarter. Rhumbline Advisers now owns 13,006 shares of the company’s stock valued at $171,000 after purchasing an additional 2,805 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Cartesian Therapeutics by 114.0% in the 2nd quarter. Marshall Wace LLP now owns 82,630 shares of the company’s stock valued at $859,000 after purchasing an additional 44,025 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Cartesian Therapeutics by 133.0% in the 2nd quarter. Bank of America Corp DE now owns 13,933 shares of the company’s stock valued at $145,000 after purchasing an additional 7,952 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Cartesian Therapeutics by 64.6% in the 3rd quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock valued at $71,000 after purchasing an additional 2,717 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Cartesian Therapeutics by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 520,722 shares of the company’s stock valued at $5,322,000 after purchasing an additional 24,356 shares during the last quarter. Institutional investors and hedge funds own 86.95% of the company’s stock.

Cartesian Therapeutics News Roundup

Here are the key news stories impacting Cartesian Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Cartesian Therapeutics and maintained a $25 price target, implying significant upside versus the current share price. Cartesian Therapeutics (NASDAQ:RNAC) Given New $25.00 Price Target at HC Wainwright
• Positive Sentiment: The company also announced it will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 19, which could help keep investor attention on its lead autoimmune-disease therapy program. Cartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
• Neutral Sentiment: HC Wainwright’s latest estimates still model continued losses across 2026 and 2027, reflecting the company’s pre-revenue, late clinical-stage profile. The firm now sees FY2026 EPS at ($4.38) and FY2027 EPS at ($3.79).
• Negative Sentiment: The analyst trimmed near-term EPS forecasts for several periods, including Q2 2026 to ($0.89) from ($0.85), Q3 2026 to ($0.94) from ($0.92), and Q4 2026 to ($1.11) from ($1.00), signaling a slightly weaker earnings outlook. Cartesian Therapeutics (NASDAQ:RNAC) Given New $25.00 Price Target at HC Wainwright

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.